C4 Therapeutics presented new biomarker data from cemsidomide clinical trials at IMS26, expanding Phase 1 findings on its immunomodulatory effects in multiple myeloma and pointing to continued early-stage development.
published
C4 Therapeutics presented new biomarker data from cemsidomide clinical trials at IMS26, expanding Phase 1 findings on its immunomodulatory effects in multiple myeloma and pointing to continued early-stage development.
Latest documented BWB result
$NBIS market result
Exit $NBIS with $3.25 profit per contract
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.